



JOSEP VERGÉS MILANO, MD, PhD

President & CEO at Osteoarthritis Foundation International (OAFI)

The Osteoarthritis Foundation International (OAFI) is an independent non-profit patient foundation devoted to the prevention and treatment of osteoarthritis (OA), along with the improvement of the quality of life of patients. We represent patients with osteoarthritis worldwide.

OAFI organizes educational and social programs focused on prevention at risk groups such as seniors, sportspeople and women over 45 in order to raise awareness. Also, OAFI promotes the development of new therapies for better treatment of OA and the improvement in quality of life of patients.

EDUCATION

- Medical Doctor (M.D.), Universitat Autònoma de Barcelona (UAB), Spain.
- Master of Science (M.Sc.) in Clinical Pharmacology. Université de Montréal, Canada. Grade A (95%).
- Philosophy Doctor in Medicine (PhD). Medicine Faculty, UAB. New European program in Clinical Pharmacology. Grade: “Cum Laude”. Barcelona, Spain.
- Specialist in Clinical Pharmacology. Ministry of Science and Education, Spain.

MEMBERSHIP

- Member of the Evaluating Committee of the French “Centre National de la Recherche Scientifique” (CNRS), INSERM and scientific board of the Lorraine region to evaluate different investigation projects and units in the rheumatology / pharmacology field.
- Member of the Scientific Council and the Management Council of the Bioiberica Cathedra / UAM (Autonomous University of Madrid) about Chronic Inflammation and Cytoprotection (CABICYC).
- Chair of the Advanced Therapies Working Group of the Spanish Clinical Pharmacology Society (SEFC).
- Member of the Expert Panel reviewing Expressions of Interest for Osteoarthritis Topic as part of the European Innovative Medicines Initiative (IMI).

SELECTION OF PUBLICATIONS

1. Vergés J., de Moragas J.M.: Consideraciones metodológicas del ensayo clínico en dermatología. *Piel*, 1991, 6: 267-271.
2. du Souich P., Vergés J., and Erill S.: Plasma protein binding and pharmacological response. Leading article. *Clinical Pharmacokinetics*, 1993, 24: 435-440.
3. Vergés J., Maurice H., Héroux L., du Souich P.: Extrahepatic metabolism of furosemide. *British Journal of Pharmacology*, 1995, 116: 2407-2412

4. Vergés J., Castañeda G. and de Moragas J.M.: Procedure for the evaluation of the bioavailability of topical formulations in vivo as the rate and extent to which the active drug product is transferred from the vehicle to the skin. *Drug Development Research*, 1995, 36: 180-185.
5. du Souich P, Vergés J. Simple approach to predict Emax when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. *Clinical Pharmacology and Therapeutics* 2001; 70 (1): 5-9.
6. Vergés, J., Castañeda-Hernández, G. On the bioavailability of oral chondroitin sulfate formulations: proposed criteria for bioequivalence studies. *Proc. West. Pharmacol. Soc.*, 2004; 47: 50-3
7. Vergés, J., Montell, E., Tomàs, E., Coronas, C., Cumelles, G., Castañeda, G., Martí, N., Möller, I. Weather conditions can influence rheumatic diseases. *Proc. West. Pharmacol. Soc.*, 2004; 47: 134-6
8. du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and antiinflammatory effects of chondroitin sulphate. *J Cell Mol Med.* 2009 Aug;13(8A):145163.
9. Möller I, Pérez M, Monfort J, Benito P, Cuevas J, Perna C, Doménech G, Herrero M, Montell E, Vergés J. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage.* 2010 Jun;18 Suppl 1:S32-40.
10. Francisco J. Blanco, Ingrid Möller, Arthrotest study group, Nerea Bartolomé, Marta Artieda, Magdalena Szczypiorska, Diego Tejedor, Antonio Martínez, Eulàlia Montell, Helena Martínez, Marta Herrero, Josep Vergés. Improved prediction of knee osteoarthritis progression by genetic polymorphisms. *The Arthrotest Study. Rheumatology (Oxford)* 2015, Jul;54(7):1236-43